Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.56 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91612 | 0.90 | NFE2L2 (0.64) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12650179 | 0.89 | NOS2 (0.57) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL16092853 | 0.88 | NOS2 (0.66) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL16215052 | 0.88 | NOS2 (0.66) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15629067 | 0.88 | NOS2 (0.66) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12227009 | 0.87 | NOS2 (0.55) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL16772027 | 0.86 | NOS2 (0.61) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10212069 | 0.85 | NFE2L2 (0.56) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10079614 | 0.85 | MBOAT4 (0.63) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL23464818 | 0.85 | NOS2 (0.59) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | ALOX12, NFE2L2, HMOX1 | NOS2 66/4885KEAP1 29/4885CYP3A4 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.